International Niemann–Pick Disease Alliance
Today, the INPDA received the attached letter (copied below), from Regan Sherman, Associate Director, Patient Advocacy Relations at Orphazyme. The letter provides the latest update regarding the introduction of an EAP programme for their investigational therapy, arimoclomol. Please do...
This week Cláubia Viegas Bender, co-founder of INPDA member group Niemann-Pick B-RS, completed her master’s degree with a project focused on ASMD Niemann-Pick disease type B. We are all hugely proud of her achievement, and we hope you will join...
Data show that Trappsol® Cyclo™, the Company’s proprietary hydroxypropyl beta cyclodextrin drug, reduces levels of trapped cholesterol in liver tissue of Niemann-Pick Disease Type C Patients GAINESVILLE, FL – (Businesswire) – December 16, 2019 – Cyclo Therapeutics, Inc. (OTCQB:...
Orphazyme receives Breakthrough Therapy Designation for arimoclomol in Niemann-Pick Disease Type C (NPC) • There are currently no US FDA-approved products for NPC • Orphazyme plans to file arimoclomol in the US in H1 2020 Copenhagen, Denmark, November 19,...
Publication describes favorable safety profile and efficacy in neurologic and other disease features in individual NPC patients following intravenous administration of drug Gainesville, FL – (Businesswire) – 31 October 2019 – Cyclo Therapeutics, Inc, (OTCQB: CTDH), a clinical stage...
Top line results are expected to be available in February 2020 GAINESVILLE, FL – (Businesswire) – October 22, 2019 – Cyclo Therapeutics, Inc. (OTCQB: CTDH), formerly CTD Holdings, Inc., a biotechnology company that develops cyclodextrin-based products for the treatment...
Announcement made in conjunction with October 19th Global Awareness Day for Niemann-Pick Disease sponsored by International Niemann Pick Disease Alliance GAINESVILLE, FL – (Businesswire) – October 18, 2019 – Cyclo Therapeutics, Inc. (OTCQB: CTDH), formerly CTD Holdings, Inc., a...
ALACHUA, FL–(Businesswire)–13 September 2019–CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that the company will provide Trappsol® Cyclo™, its proprietary hydroxypropyl beta...
Inc. is pleased to confirm that the Clinical Trial IB1001-201, “Effects of N-Acetyl-L-Leucine on Niemann-Pick type C Disease (NPC): A multinational, multi-center, open-label, rater-blinded Phase II study” is open for recruitment in the United Kingdom. IB1001-201 is a multinational...
CTD is also a proud sponsor of the conference, for the 4th year running… ALACHUA, FL–(Businesswire)–11 September 2019–CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical...